Background and objective: Intratumoral administration of chemotherapeutic agents is a treatment modality that has proven efficacious in reducing the recurrence of tumours and increases specificity of treatment while minimizing systemic side effects. Direct intratumoral injection of malignant airway obstruction has potential therapeutic benefits but tissue drug concentrations and side-effect profiles are poorly understood. Methods: Bronchial wall injection of generic paclitaxel (PTX) (102 injections of 0.05, 0.5, 1.5 or 2.5 mg/mL in 10 healthy pigs), saline (14 injections in 2 healthy pigs) or Abraxane (ABX) (24 injections of 0.5 mg/mL in 4 healthy pigs) was performed with a microneedle infusion catheter. Local histopathology, plasma and tissue PTX concentrations were evaluated at 7, 20 or 28 days post-injection. Results: Injection of generic PTX directly into the bronchial wall at doses up to 1.5 mg/mL only caused minimal tissue injury. Dose-limiting tissue reaction was observed at 2.5 mg/mL. Plasma PTX was detectable for up to 5 days but not at 28 days, with area under the curve (AUC) (0-5d) 20-to 50-fold lower than the AUC (0-∞) of 6300 ng h/mL for the approved intravenous dose. At 7 and 28 days post-injection, bronchial PTX tissue concentrations were above a 10-nmol/L cancer therapeutic level. PTX was not found in peripheral tissues. Similar results were observed between ABX and generic PTX. Conclusion: Results of these studies confirm the administration of PTX directly into the bronchial wall is safe and feasible. PTX was detectable in plasma for <7 days but tissue concentrations remained therapeutic throughout the follow-up period.
INTRODUCTION
Obstruction of the central airways, the trachea and mainstem bronchi, results from many disease processes including malignant growths. According to the National Cancer Institute, in 2016, it is estimated there will be 224 390 new cases of lung cancer, representing 13.3% of all cancer cases. The disease is the second most common type of cancer and the deadliest, with a 5-year survival rate of 17.7%. 1 Patients with lung cancer experience significant morbidity from airway involvement due to persistent cough, dyspnoea, wheezing, stridor and obstructive pneumonia.
In patients with inoperable malignant central airway obstruction due to non-small cell lung cancer, prognosis is generally poor, although therapeutic bronchoscopic procedures are often performed to remove the obstruction to improve quality of life and possibly improve survival. 2 In an effort to further reduce tumour mass and improve outcomes of therapeutic bronchoscopy in patients with malignant airway obstruction, the intratumoral administration of chemotherapeutic agents has been proposed as an adjunctive therapy. In animal models and in patients with lung cancer, this approach has demonstrated successful results in delaying tumour recurrence. [3] [4] [5] [6] [7] [8] [9] A new drug delivery catheter, the Blowfish Transbronchial Micro-Infusion Catheter (Mercator MedSystems, Emeryville, CA, USA) was developed to directly deliver medication safely and reliably into the airway wall by way of a microneedle port. Preliminary results confirmed the effectiveness of the catheter to deliver small volumes (up to 3 mL) of liquid to bronchial walls without tissue injury. 10 In the present report, we have characterized the pharmacokinetics and tissue injury associated with the injection of paclitaxel (PTX) directly into the bronchial wall of pigs.
METHODS

Device description
The device has been described in detail elsewhere. 10 Briefly, the Blowfish device (Fig. 1) is a drug delivery catheter passable through the working channel of a flexible bronchoscope. At the distal end of the catheter, a 0.9 mm long, 34-gauge needle is completely sheathed by a deflated semi-rigid polymer balloon. Once positioned at the target site, the balloon is inflated, which pushes the microneedle perpendicularly into the bronchial wall, and therapeutic agents are slowly injected. The balloon is then deflated, withdrawing the needle from the bronchial wall and re-sheathing it for removal through the bronchoscope.
Animal preparation
This study was approved by the Beth Israel Hospital Institutional Animal Care and Use Committee (IACUC) approval A3153-01 for protocol 0802009. All interventional procedures were performed by an independent, AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care)-accredited preclinical research organization (CBSET Inc., Lexington, MA, USA). Following an overnight fast, juvenile Yorkshire pigs of both sexes and weighing approximately 50 kg were pre-medicated with either dexamethasone (20 mg PO (by mouth, orally)), diphenhydramine (50 mg i.v.), cimetidine (300 mg i.v. or ranitidine (50 mg i.v.) to prevent severe hypersensitivity reactions, and anaesthetised per a standard protocol developed by CBSET.
The experimental protocols consisted of three studies to examine generic PTX (Bristol-Myers Squibb, New York, NY, USA) or the nanoparticle-albumin-bound PTX, Abraxane (ABX) (Celgene Corporation, San Francisco, CA, USA), with treatments summarized in Table 1 . In all studies, pharmacokinetics and local tissue injury were assessed after necropsy. In Study 2, systemic toxicity was also assessed. In each study, PTX or ABX was diluted in sterile saline and 20% contrast medium (Isovue300, Bracco Diagnostics, Milan, Italy) by volume to reach final concentrations. Studies were not intended for direct comparison, but rather to demonstrate feasibility, pharmacokinetics and safety across the range of doses, formulations and sacrifice endpoints studied. Study 3 did not include a control group due to the prior study of saline (vehicle) controls in a preliminary safety study, previously published by Tsukada et al.
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Bronchoscopic procedure
The bronchoscopic procedure has been described in detail elsewhere. 10 Briefly, a flexible bronchoscope Figure 1 The Blowfish Transbronchial Micro-Infusion Catheter.
(Olympus 1T160, San Jose, CA, USA) was inserted into the airways through the endotracheal tube. The catheter balloon was primed with a mixture of 20% contrast medium and saline and the separate drug lumen of the catheter was primed with the PTX or saline solution.
After direct bronchoscopic visualization of the treatment site (bronchi with diameter 3-16 mm), the balloon was inserted through the working channel of the bronchoscope under fluoroscopic and visual guidance, inflated up to 2 atmospheres of pressure and 1 mL of the PTX solution was injected into the bronchial wall. After each injection, the balloon was deflated and withdrawn into the bronchoscope while navigating to the next treatment site. At the end of the procedure, all animals were allowed to recover and returned to the animal care facilities at CBSET. After the predetermined follow-up period, the animals were euthanized according to a standard CBSET protocol and the lungs were removed for histopathology and tissue PTX concentration analyses.
Blood and tissue sampling
In Study 2, immediately prior to the injections and then after the injections at hours 1, 4, 16, 24 and 36 and days 2, 3, 4, 5 and 28, venous blood (17 mL) was drawn and transferred into vacutainers containing either EDTA (Ethylenediaminetetraacetic acid), no additive or sodium heparin for the assessment of whole blood haematology, serum chemistry and plasma pharmacokinetic parameters, respectively. After centrifugation, aliquots of serum and plasma samples were transferred to plastic screw top vials and immediately frozen at −80 C until processed. The whole blood and serum samples were processed at Antech Diagnostics GLP (Morrisville, NC, USA) and the plasma samples were processed at Bioanalytical Systems Inc. (McMinnville, OR, USA).
For the determination of tissue PTX concentration, at least 6 cm of bronchial tissue from selected injection sites was removed along with the surrounding parenchyma at necropsy. The tissues were sectioned with a sharp knife into 0.5 or 1 cm segments, transferred to screw top vials and frozen at −80 C until processed by tissue homogenization, extraction and LC/MS/MS at Bioanalytical Systems Inc.
Histopathology
Lungs were inflated with a 10% neutral buffered formalin solution for at least 24 h. They were examined macroscopically for any evidence of gross changes, trimmed in 3 mm increments around each infusion site, paraffin embedded, sectioned and stained with HE. All bronchial sections were analysed by a blinded pathologist from CBSET for evidence of tissue response including injury, inflammation, epithelial loss, haemorrhage, fibrin and thrombus per the semi-quantitative scoring scale described by Tsukada et al. 10 and depicted in Table 2 .
RESULTS
A total of 14 pigs with 128 injections were included in the present study. Overall, the bronchoscopic procedure and the injection of PTX or saline directly into the bronchial wall were safe and feasible. Other than a transient reaction to PTX or the excipient (Cremophor EL) in a single animal administered 1.5 mg/mL PTX (from Study 2), there were no injection or PTX-related abnormalities in the clinical and gross pathology observations up to 28 days post-injection. In subjects receiving 2.5 mg/mL PTX, bronchoscopy and necropsy at 7 days revealed abnormal hyperaemia and focal tissue necrosis around two injection sites, accompanied by minimal bleeding into the parenchyma. All doses ≤1.5 mg/mL were associated with absent to negligible tissue injury. No periprocedural morbidity occurred in any study and all injections were considered successful.
Histopathology assessment
Histopathology scoring results are reported in Table 3 , including the data reported by Tsukada et al. for 1.0 mL volume injections of saline vehicle control 10 ('Ref10' in Table 3 ), which are consistent with the 1.0 mL volumes injected in these studies.
In Study 1, the local tissue reaction following the delivery of PTX directly into the bronchial adventitia was assessed. At 7 days post-treatment, all bronchi injected with 0.05 and 0.5 mg/mL doses of PTX showed mild inflammation and minimal lymphocyte infiltrations which were considered part of normal bronchus-associated lymphoid tissue. There was Endobronchial intratumoral paclitaxel minimal bronchial injury and epithelial loss, and no bronchial lumen thrombus. In bronchi injected with 2.5 mg/mL (2 mL volume), bronchoscopic follow-up and histology revealed marked hyperaemia, multifocal necrosis of bronchial cartilage, peribronchial tissue and pulmonary parenchyma, and full thickness airway wall damage and minimal bleeding into lung parenchyma associated with moderate inflammation. These reactions were observed in three of four bronchial segments injected with the 2.5 mg/mL dose and analysed by histopathology. Bronchial lumen thrombus and epithelial loss were minimal, while bronchial injury was moderate with smooth muscle laceration. Given the tissue injury, the subsequent studies were conducted with 1.5 mg/mL as the highest dose of PTX. In Study 2, similar to the results at 7 days, the injection of both 0.5 and 1.5 mg/mL of PTX was associated with limited local tissue responses (including bronchi and peribronchial lung parenchyma) at 28 days (absent to negligible inflammation, epithelial loss, haemorrhage, fibrin and thrombus).
In Study 3, limited local tissue responses (including bronchi and peribronchial lung parenchyma) were seen 7 and 20 days after ABX (0.5 mg/mL) was injected into the bronchial wall.
Plasma PTX concentration
In Study 2, plasma PTX was measurable up to 5 days post-injection for both the 0.5 and 1.5 mg/mL drug doses, but not at 28 days (see Fig. 2 ). The area under the curve (AUC) (0-5d) for the 0.5 mg/mL dose was 122 AE 15 ng h/mL (average total dose of 5.2 AE 0.3 mg across 10.3 AE 0.6 injections) and 320 AE 61 ng h/mL with the 1.5 mg/mL dose (total dose of 15 mg in each animal), which are both more than an order of magnitude below the AUC 0-∞ of 6300 ng h/mL for a 135 mg/ m 2 dose systemically administered over 24 h.
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Tissue PTX concentration From Study 1, the average PTX concentrations at 7 days after PTX delivery were determined over 3 cm of bronchial tissue centred around the injection sites as detected from the greatest levels of PTX from among the 6 cm of tissue sampled. The 0.05, 0.5 and 2.5 mg/ mL doses of PTX led to tissue concentrations of 42 AE 17 nmol/L (range: 19.1-57.7), 99 AE 39 nmol/L (range: 28.6-142) and 143 AE 64 nmol/L (range: 98.5-189), respectively, which were above the reported 10-30 nmol/L cancer therapeutic level. 12 From Study 2, the average PTX concentrations at 28 days after 0.5 and 1.5 mg/mL PTX doses were 15.3 AE 16.4 and 5.1 AE 3.4 nmol/L, respectively. However, PTX was also detected in the two bronchial samples taken from animals receiving control vehicle injections (6.0 and 13.0 nmol/L), indicating that a likely contamination occurred during harvest and sectioning of treated and control tissues, which made a definitive conclusion as to the tissue concentration difficult. While the sectioning of tissue was performed on a necropsy table using a sharp knife and cutting board, the cutting board and knife were cleaned but not sanitized between subjects and could have contaminated from early subjects to those cut later. Of relevance, the two control subjects that had received vehicle injections were necropsied in the same day and subsequent to four subjects that had received PTX injection; thus cross-contamination was potential. Systematic overestimation of the PTX assay was unlikely since results from several bronchial segments (11 out of 142 samples) and distant organs using the same assay showed a lack of PTX in tissues (below the limits of quantitation of 0.3 ng/g or 0.35 nmol/L). The results of 0.5 mg/mL dosage from Studies 1 and 2 are illustrated in Figure 3A . PTX was not detected in heart, liver or kidney of any subjects in Study 2. From Study 3, the average PTX concentrations at 7 and 20 days after 0.5 mg/mL ABX delivery were determined over 3 cm of bronchial tissue centred around the injection sites. The concentration of PTX at 7 and 20 days was 154 AE 43 and 27 AE 20 nmol/L, respectively. Distribution along the bronchi was Figure 2 The plasma paclitaxel concentration peaked at 1 min (C max = 12.6 AE 6.2 ng/mL) with the 0.5 mg/mL dose and at 1 h (C max = 24.1 AE 5.1 ng/mL) with the 1.5 mg/ mL dose and was below detection limits by 28 days. Statistical comparison between PTX and ABX showed P < 0.02 for proximal segments and P = NS for middle and distal segments with a Student's t-test analysis. 5.2 mg total dose (N = 3 pigs); 15 mg total dose (N = 4 pigs); lower limit of quantitation. AUC, area under the curve; NS, non-significant.
determined in Studies 1 and 3, with comparative results of 0.5 mg/mL dosage shown in Figure 3B .
DISCUSSION
The present study evaluated the safety and pharmacokinetics of PTX delivered directly into porcine bronchial tissue using the Blowfish Transbronchial MicroInfusion Catheter. While dose limiting toxicities were observed with the administration of 2 mL doses of 2.5 mg/mL PTX, the administration of varying doses of PTX of up to 1.5 mg/mL was associated with negligible tissue injury and inflammation, processes that did not deteriorate throughout the 28-day follow-up period. PTX was detectable in plasma for at least 5 days but not at 28 days, with an AUC (0-5d) more than an order of magnitude below the AUC (0-∞) for the approved i.v. formulation, suggesting reduced systemic exposure. PTX was detectable in bronchial tissues 28 days postinjection in concentrations above the 10 nmol/L cancer therapeutic level, based on in vitro results that have shown IC 50 of less than 10 nmol/L in H460 (p53 wildtype) and H358 (p53 null) cells when exposed to PTX for 96 or 72 h, respectively. 12 While there was a likely contamination of control samples in 28-day tissues during processing, it is assumed that the control tissues were contaminated from drug that remained on the necropsy instrumentation, since control animals were harvested after treated animals but were never otherwise exposed to PTX. With minimal tissue injury and optimal tissue concentrations, our results collectively demonstrate the direct injection of PTX in a concentration of 1.5 mg/mL into the bronchial wall of a porcine model is safe and feasible and may represent an attractive adjunctive therapy to therapeutic bronchoscopy and systemic chemotherapy for patients with malignant airway obstruction.
PTX, a microtubule stabilizer that selectively arrests cells in the G2/M phase of the cell cycle, is a member of the taxane class of anticancer drugs and one of the most common chemotherapeutic agents used against many forms of cancer. Although highly effective, the systemic administration of PTX is associated with significant and debilitating side effects. The intratumoral administration of chemotherapeutic agents is a treatment modality that has been shown to be safe and efficacious in reducing or preventing tumour growth in both animals and humans. [3] [4] [5] [6] [7] [8] [9] The advantages of this approach are numerous. By administering the chemotherapeutic agent directly into the tumour, the specificity of treatment is greater and the dosage necessary to induce cytotoxic effects can be reduced, thereby minimizing systemic side effects.
Results of the present study extend previous findings 10 of Blowfish device safety and feasibility in that the direct injection of PTX into the bronchial wall appears safe as evidenced by histopathology analysis.
For the intratumoral approach to be effective, the drug must be retained in the tissue for extended periods of time. 6 In our study, following 1 mL injections of 0.5 mg/mL, PTX was present in bronchial tissues at concentrations of 99 nmol/L at 7 days and 15.3 nmol/L at 28 days, which are both above the 10 nmol/L that has been reported as effective with 4 days of exposure. 12 However, because of likely contamination in 28-day samples (an average PTX concentration of 9.5 nmol/L was found in the bronchi of the two pigs treated with the drug vehicle only) it was difficult to conclude the retained concentration of PTX. It is also important to note that PTX distribution was limited to the local bronchial and lung tissue and did not redistribute into other major organs (heart, liver or kidney) at detectable 28-day levels. In comparative studies of ABX and PTX, it was noted that the distribution and retention of PTX in tissues were not significantly different, thus the less expensive generic material was chosen to advance into clinical trials.
The limitations of the present studies include that they were not performed into animal models of airway tumours, as no such models are known to exist. While mouse models of xenograft tumours are available and have been studied with intratumoral PTX injection [3] [4] [5] [6] no intratumoral pharmacokinetics have been reported with direct injection of ABX or PTX specifically.
Based on these promising preclinical results, we have initiated a prospective, open label clinical trial (the Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients, NCT02066103) to assess the safety and feasibility of the local delivery of a 1.5 mg/mL, 1 mL dose of PTX into the bronchial wall of patients with malignant airway obstruction secondary to non-small cell lung cancer after they have undergone bronchoscopic recanalization.
In conclusion, the administration of PTX directly into the bronchial wall using the Blowfish Transbronchial Micro-Infusion Catheter has been shown to be feasible with mild to no histopathologic observations of the bronchial tissue. Drug retention in tissue remained above proposed therapeutic levels for at least 28 days. Given PTX was only detectable in plasma for a few days after injection, coupled with lasting tissue retention at the target site and none at other organs, we believe the addition of this new technique to the contemporary chemotherapeutic armamentarium has the potential to improve patient outcomes and quality of life while minimizing systemic side effects.
